BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 29784852)

  • 1. Plasma and Intrapulmonary Concentrations of Cefepime and Zidebactam following Intravenous Administration of WCK 5222 to Healthy Adult Subjects.
    Rodvold KA; Gotfried MH; Chugh R; Gupta M; Patel A; Chavan R; Yeole R; Friedland HD; Bhatia A
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29784852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of cefepime/zidebactam (WCK 5222) against recent Gram-negative isolates collected from high resistance settings of Greek hospitals.
    Bhagwat SS; Legakis NJ; Skalidis T; Loannidis A; Goumenopoulos C; Joshi PR; Shrivastava R; Palwe SR; Periasamy H; Patel MV; Chatzipanagiotou S;
    Diagn Microbiol Infect Dis; 2021 Jul; 100(3):115327. PubMed ID: 33744624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of human-simulated bronchopulmonary exposures of cefepime, zidebactam and the combination (WCK 5222) against MDR Pseudomonas aeruginosa in a neutropenic murine pneumonia model.
    Kidd JM; Abdelraouf K; Nicolau DP
    J Antimicrob Chemother; 2020 Jan; 75(1):149-155. PubMed ID: 31641765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Novel β-Lactam Enhancer Zidebactam Augments the
    Bhagwat SS; Periasamy H; Takalkar SS; Palwe SR; Khande HN; Patel MV
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative in vivo activity of human-simulated plasma and epithelial lining fluid exposures of WCK 5222 (cefepime/zidebactam) against KPC- and OXA-48-like-producing Klebsiella pneumoniae in the neutropenic murine pneumonia model.
    Lasko MJ; Abdelraouf K; Nicolau DP
    J Antimicrob Chemother; 2021 Aug; 76(9):2310-2316. PubMed ID: 34096601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent β-Lactam Enhancer Activity of Zidebactam and WCK 5153 against Acinetobacter baumannii, Including Carbapenemase-Producing Clinical Isolates.
    Moya B; Barcelo IM; Bhagwat S; Patel M; Bou G; Papp-Wallace KM; Bonomo RA; Oliver A
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases.
    Sader HS; Rhomberg PR; Flamm RK; Jones RN; Castanheira M
    J Antimicrob Chemother; 2017 Jun; 72(6):1696-1703. PubMed ID: 28333332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. WCK 5222 (Cefepime-Zidebactam) Antimicrobial Activity against Clinical Isolates of Gram-Negative Bacteria Collected Worldwide in 2015.
    Sader HS; Castanheira M; Huband M; Jones RN; Flamm RK
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28242660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria.
    Livermore DM; Mushtaq S; Warner M; Vickers A; Woodford N
    J Antimicrob Chemother; 2017 May; 72(5):1373-1385. PubMed ID: 28158732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of the
    Avery LM; Abdelraouf K; Nicolau DP
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30181365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of cefepime/zidebactam (WCK 5222) against Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter baumannii endemic to New York City medical centres.
    Khan Z; Iregui A; Landman D; Quale J
    J Antimicrob Chemother; 2019 Oct; 74(10):2938-2942. PubMed ID: 31298277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent "β-Lactam Enhancer" Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones.
    Moya B; Barcelo IM; Bhagwat S; Patel M; Bou G; Papp-Wallace KM; Bonomo RA; Oliver A
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28289035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma and Intrapulmonary Concentrations of ETX2514 and Sulbactam following Intravenous Administration of ETX2514SUL to Healthy Adult Subjects.
    Rodvold KA; Gotfried MH; Isaacs RD; O'Donnell JP; Stone E
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30126953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Characterization of WCK 5222 (Cefepime/Zidebactam)-Resistant Mutants Developed from a Carbapenem-Resistant Pseudomonas aeruginosa Clinical Isolate.
    Pan X; Zhao X; Song Y; Ren H; Tian Z; Liang Q; Jin Y; Bai F; Cheng Z; Feng J; Wu W
    Microbiol Spectr; 2022 Feb; 10(1):e0267821. PubMed ID: 35196805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inoculum effects of cefepime/zidebactam (WCK 5222) and ertapenem/zidebactam (WCK 6777) for Enterobacterales in relation to β-lactamase type and enhancer effect, as tested by BSAC agar dilution.
    Mushtaq S; Vickers A; Chaudhry A; Woodford N; Livermore DM
    J Antimicrob Chemother; 2022 Jun; 77(7):1916-1922. PubMed ID: 35368056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Plasma and Intrapulmonary Concentrations of Nafithromycin (WCK 4873) in Healthy Adult Subjects.
    Rodvold KA; Gotfried MH; Chugh R; Gupta M; Friedland HD; Bhatia A
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-Center Evaluation of the Pharmacokinetics of WCK 5222 (Cefepime-Zidebactam Combination) in Subjects with Renal Impairment.
    Preston RA; Mamikonyan G; DeGraff S; Chiou J; Kemper CJ; Xu A; Mastim M; Yeole R; Chavan R; Patel A; Friedland HD; Bhatia A
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30397067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial activity of cefepime/zidebactam (WCK 5222), a β-lactam/β-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018-19).
    Sader HS; Mendes RE; Duncan LR; Carvalhaes CG; Castanheria M
    J Antimicrob Chemother; 2022 Sep; 77(10):2642-2649. PubMed ID: 35897129
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Karlowsky JA; Hackel MA; Bouchillon SK; Sahm DF
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32928739
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Almarzoky Abuhussain SS; Avery LM; Abdelraouf K; Nicolau DP
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.